Practical considerations and challenges for germline genetic testing in patients with prostate cancer: Recommendations from the germline genetics working group of the PCCTC

Brittany M. Szymaniak, Lauren A. Facchini, Veda N. Giri, Emmanuel S. Antonarakis, Tomasz M. Beer, Maria I. Carlo, Daniel C. Danila, Mallika Dhawan, Daniel George, Julie N. Graff, Shilpa Gupta, Elisabeth Heath, Celestia S. Higano, Glenn Liu, Ana M. Molina, Channing J. Paller, Akash Patnaik, Daniel P. Petrylak, Zachery Reichert, Matthew B. RettigCharles J. Ryan, Mary Ellen Taplin, Jake Vinson, Young E. Whang, Alicia K. Morgans, Heather H. Cheng, Rana R. McKay

Research output: Contribution to journalReview articlepeer-review

31 Scopus citations

Abstract

Germline genetic testing is now routinely recommended for patients with prostate cancer (PCa) because of expanded guidelines and options for targeted treatments. However, integrating genetic testing into oncology and urology clinical workflows remains a challenge because of the increased number of patients with PCa requiring testing and the limited access to genetics providers. This suggests a critical unmet need for genetic services outside of historical models. This review addresses current guidelines, considerations, and challenges for PCa genetic testing and offers a practical guide for genetic counseling and testing delivery, with solutions to help address potential barriers and challenges for both providers and patients. As genetic and genomic testing become integral to PCa care, developing standardized systems for implementation in the clinic is essential for delivering precision oncology to patients with PCa and realizing the full scope and impact of genetic testing.

Original languageEnglish (US)
Pages (from-to)811-819
Number of pages9
JournalJCO Oncology Practice
Volume16
Issue number12
DOIs
StatePublished - Dec 1 2020

ASJC Scopus subject areas

  • Oncology
  • Health Policy
  • Oncology(nursing)

Fingerprint

Dive into the research topics of 'Practical considerations and challenges for germline genetic testing in patients with prostate cancer: Recommendations from the germline genetics working group of the PCCTC'. Together they form a unique fingerprint.

Cite this